The use of Eli Lilly 's Mounjaro for weight loss can pull shoppers away from the snack aisle — though the transition will likely be gradual, according to Morgan Stanley. Mounjaro belongs to a class of drugs gaining popularity for their weight-loss capabilities. While its growth has been stymied by hurdles to off-label use, Mounjaro should see Food and Drug Administration approval to treat obesity by the end of 2023, analyst Pamela Kaufman said.
are likely to be most impacted by growing adoption of anti-obesity drugs, but believe the impact will be modest in the near-term as adoption is expect to increase gradually." Mounjaro patients cut calorie intake at lunch by 71%, according to the study. More specifically, those taking the medication reduced intake to 268 calories at week six from 955 at the start, while those taking the placebo increased their lunchtime calories over the course of the study.
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Morgan Stanley's Wilson: Next rally attempt will fail as investors are punishing earnings reports.Critical information for the U.S. trading day
Read more »